Učitavanje...
60 mg·m(−2)·d(−1)柔红霉素联合标准剂量阿糖胞苷诱导治疗≤65岁初治急性髓系白血病患者的疗效和安全性分析
OBJECTIVE: To evaluate the long-term safety and efficacy of high-dose daunorubicin (DNR) (60 mg·m(−2)·d(−1)) combined with standard dose of cytarabine (DA) as induction therapy in patients under 65 years old with newly diagnosed acute myeloid leukemia (AML). METHODS: The complete remission (CR) rate...
Spremljeno u:
| Izdano u: | Zhonghua Xue Ye Xue Za Zhi |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Editorial office of Chinese Journal of Hematology
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7364868/ https://ncbi.nlm.nih.gov/pubmed/27801323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.015 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|